We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our mission is to transform cancer treatment for patients by developing evorpacept as a first-in-class foundational checkpoint immunotherapy

Evorpacept Mechanism of Action

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, evorpacept (ALX148), will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue evorpacept as a potentially critical component for future combination treatments in oncology.

Latest News updated at 11:45:08 UTC

Sep 06, 2023

ALX Oncology Realigns Executive Leadership Team

Aug 31, 2023

ALX Oncology Announces September Investor Conference Participation

Aug 10, 2023

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update


ALX Oncology today announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D. as Chief Executive Officer, effective September 6, 2023: https://bit.ly/45XDM7k

ALX Oncology today announced that management will participate in two upcoming investor conferences: https://bit.ly/47U6nMm

ALX Oncology today reported financial results for the second quarter ended June 30, 2023, and provided an update on the Company’s portfolio of clinical programs in development: https://bit.ly/3QCPorN

Load More

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, evorpacept, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.